Introduction
The connection between inflammation and atherosclerosis is not of recent origin. Microscopic observations beginning in the 19th century described the presence of inflammatory reddening and inflammatory cells within human plaques [1, 2] . Today it is acknowledged that development of atherosclerosis is a unique type of chronic inflammatory response that involves both innate and adaptive immune mechanisms [3] . The development of animal models with cholesterol feeding, blood vessel injury and systemic infection has further supported the role of inflammation in the initiation and progression of atherosclerosis. The development of immunocytochemical and flow cytometric approaches with inflammatory cell type specific antibodies has now clearly established that atherosclerotic plaques at all stages of development contain multiple types of inflammatory cells including macrophages, dendritic cells, CD4 and CD8 positive T lymphocytes, B lymphocytes, mast cells and occasionally neutrophils and other granulocytes [4, 5] . There is also a rapidly emerging new paradigm that suggests that several types of inflammatory cells within plaques have multiple phenotypes and can even change phenotype after entry into the plaques depending on the exposure to specific micro-environmental cues [6] . In this short review the focus will be on distinguishing between direct inflammatory mechanisms that occur within the wall of the blood vessel and are thought to be responsible for the initiation of the disease process and indirect mechanisms where inflammation at nonvascular sites contributes to the progression and destabilization of the plaques.
Direct mechanisms: pro-inflammatory factors that initiate the disease process
Because of page restrictions, I will not review the natural history of the development of atherosclerotic plaques but refer the reader to a number of excellent recently published reviews [5, 7, 8] . However, what is still unknown is precisely what enters the normal human blood vessel that sets in motion the subsequent activation of the endothelium to express adhesion molecules and leads to the recruitment of inflammatory cells into the intima. Today, lipids are still the leading candidates and the lipid retention hypothesis has been supported by much experimental evidence [9] . Although Anitschkow first demonstrated that cholesterol feeding to rabbits led to the formation of lipid loaded cells within the intima [10], more definitive evidence was provided by experiments demonstrating that LDL particles that were labeled with a nondegradable radioactive probe accumulated at lesion susceptible branch points within days of initiating cholesterol feeding in rabbits [11, 12] . However, those experiments did not clarify whether the simple accumulation of LDL particles trapped by interactions with matrix molecules [9] is sufficient to activate the inflammatory response or whether the LDL particles must be modified by oxidation of the fatty acids, phospholipids, and cholesterol or by other modifications. There is experimental evidence showing that oxidized lipids induce expression of adhesion molecules by endothelial cells [13, 14] ,66]. A critical question to be addressed by future research is how these different phenotypes play roles in stimulating or preventing the progression of human plaques to clinically relevant stages of the disease.
Indirect mechanisms: inflammation at nonvascular sites that contributes to the progression of atherosclerotic lesions
It is well established that people with autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, and ankylosing spondylitis have an increased risk of mortality from cardiovascular disease [67] . This gave the first hint that inflammatory disorders at sites other than the blood vessel could contribute in a number of ways to the chronic inflammation within the artery wall. Smoking is also a well established risk factor for CVD mortality as are respiratory infection, air pollution exposure and possibly gastric and periodontal infections [27, 68, 69 ]. The outstanding question is what the mechanisms are by which all of these nonvascular inflammatory conditions contribute to the ongoing inflammation in atherosclerotic lesions.
Perhaps the most obvious answer is that cytokines and other factors that are generated at nonvascular sites can be released into the circulation and taken up into the wall of the blood vessel. There are increases in plasma cytokines associated with the above autoimmune diseases [67] and we have shown that respiratory infection of mice with C. pneumoniae stimulates an acute phase response with measurable increases in plasma cytokines [70] . Exposure of mice to concentrated diesel exhaust or ambient particles derived from vehicular emissions and other sources of pollution also stimulates increases in cytokines [71] [72] [73] . Air pollution exposure as well as smoking can lead to the oxidation of lung surfactant phospholipids [74] that may be picked up by circulating lipoproteins and delivered to the blood vessel. As noted, activated inflammatory cells such as C. pneumoniae infected monocytes and macrophages may also exit nonvascular sites of inflammation and subsequently be recruited to the atherosclerotic plaque [31] . This may also be the case with inflamed peri-adventitial adipose tissue [75 ] . There is emerging evidence that obese people with increased visceral fat have increased numbers of macrophages and lymphocytes in the stromal vascular compartment of the adipose tissue. These cells are also sources of cytokines such as TNF-alpha that are thought to contribute to insulin resistance in liver and muscle [76] . It is quite conceivable that these activated inflammatory cells and/or secreted cytokines can enter the adventitia and vasa vasorum and be delivered to the plaque [75] (Figure 1 ).
Another indirect mechanism that has gained recent acceptance is the inflammation associated formation of dysfunctional HDL [77] . For decades, HDL cholesterol has been thought of as the 'good' cholesterol as epidemiologic data consistently demonstrated a strong association between plasma HDL cholesterol levels and a reduced risk of CVD [78] . It is now becoming clear that HDL cholesterol may not be an adequate marker of reduced risk of CVD as recent clinical trials with agents that increase HDL cholesterol coupled with genome wide association studies have shown that there is no reduction in risk with elevation of HDL cholesterol [77] . HDL is thought to play a protective role in CVD primarily by picking up cholesterol from the plaque and transporting it to the liver to be converted to bile and then excreted, a process referred to as reverse cholesterol transport. However, HDL also has anti-inflammatory and anti-oxidant properties that can be protective of atherosclerosis. These properties are most likely dependent on the proteins carried on the HDL particle such as the anti-oxidant enzyme paraoxonase [79, 80] . Patients with rheumatoid arthritis and systemic lupus erythematosus have HDL with a reduced capacity to inhibit endothelial expression of adhesion molecules and the oxidation of LDL [61] . In fact, patients with established coronary artery disease also appear to have dysfunctional HDL [81] . Furthermore, mice infected with influenza A [82] or with C. pneumoniae (70) or exposed to concentrated ambient particles derived primarily from vehicular emissions also have dysfunctional HDL [83] .
Finally, there are autoantibodies that recognize antigens within atherosclerotic plaques but that are thought to be generated in response to antigens generated elsewhere. For example, autoantibodies that recognize oxidized phospholipids within the plaques are known to be induced in response to oxidized phospholipids within bacterial cell walls or the membranes of apoptotic cells [84 ,85] . It is also conceivable that oxidized phospholipids generated from lung surfactant following exposure to air pollution may also contribute to the generation of these autoantibodies [70] . There are also autoantibodies that recognize cholesterol and oxidized cholesterol [86, 87] and bacterial heat shock proteins and that crossreact with human heat proteins [88] . Thus, these autoantibodies could form antibody:antigen complexes within the developing plaque that could further contribute to the chronic inflammatory response of atherosclerosis.
Conclusions
It is now widely accepted that the development of atherosclerosis involves a chronic inflammatory response that includes both innate and adaptive immune mechanisms. However, there continue to be questions regarding the factors that directly stimulate these mechanisms within the intima of the blood vessel and set in motion the initiation and progression of the disease process. There are multiple possibilities that include lipid deposition and oxidation, accumulation of cell derived microparticles, and nonlipid lipoprotein associated factors. It is now clear that inflammation at nonvascular sites can contribute to the progression of atherosclerosis. These include multiple autoimmune diseases, smoking, respiratory infection and pollution exposure. There are still outstanding questions concerning the mechanisms by which nonvascular inflammation contributes to the chronic inflammation in the plaque. Possibilities include increases in plasma cytokines and other pro-inflammatory factors generated at nonvascular sites, migration and recruitment of already activated inflammatory cells and the formation of dysfunctional HDL. The mandate for the future is to verify that these direct and indirect mechanisms contribute to human atherosclerosis and to develop appropriate preventive and therapeutic approaches. 
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